Board

	Mark Clisby - President	Senior roles in the public sector, universities and NGOs, CEO of two social enterprises
	Martin Wilkinson – Vice President	Director of Clinical Studies for a not-for-profit healthcare company
	Andrew Bretherton – Secretary	A banking lawyer with over 40 years experience
	Russell Smith – Treasurer	Accountant and passionate supporter of not-for-profit organisations
	Rebecca Davey – Member	CEO, Arthritis ACT
	Caitlin Phillips-Peddlesden – Member	International development expert, Oxfam Australia, specialising in monitoring and evaluation

Latest

Research Digest 01/12/22

Welcome to the 90th edition of the Research Digest. This month's edition features ME/CFS studies investigating microclotting and antibody targeting of gut bacteria. Also presented, is the study of serum samples from post-covid syndrome and -/+ME/CFS patients, to further study endothelial dysfunction and the role of angiogenesis in both study groups. And finally, the recent ABC news article featuring Chris Armstrong and Anne Wilson is highlighted.
Change to eligibility for oral COVID-19 treatments

The Pharmaceutical Benefits Advisory Committee recommended changes to the Pharmaceutical Benefits Scheme (PBS) eligibility criteria of oral treatments for COVID-19.
Living with Severe ME/CFS

It is estimated 25% of individuals living with ME/CFS have severe or very severe symptoms. Ricky Buchanan worked with Emerge Australia to create some tips and hacks for those living with severe ME/CFS.
Post-Infection disease: Australia’s 10th National Health Priority Area

Emerge Australia strongly advocates for the Federal Department of Health to make post-infection disease Australia’s 10th National Health Priority Area (NHPA). The number of Australians living with post-infection disease is rapidly increasing, predicted to be over half a million by the end of 2022, due to a new cohort of post-infection disease patients: those with Long COVID.